Post-Conference Perspectives: Advances in the Management of Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia

home / news-network / post-conference-perspectives-advances-in-the-management-of-newly-diagnosed-ph-acute

Updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023.

Defining and Diagnosing Philadelphia Chromosome-Positive (Ph+) ALL

EP. 1: Defining and Diagnosing Philadelphia Chromosome-Positive (Ph+) ALL

June 28th 2023

Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.

Evolving Standard of Care for Patients Diagnosed with Ph+ ALL

EP. 2: Evolving Standard of Care for Patients Diagnosed with Ph+ ALL

June 28th 2023

Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.

Recent Updates from the PhALLCON Study

EP. 3: Recent Updates from the PhALLCON Study

July 5th 2023

Medical experts highlight recent findings from the PhALLCON study.

Ponatinib and Blinatumomab Use in Patients with Newly Diagnosed Ph+ ALL

EP. 4: Ponatinib and Blinatumomab Use in Patients with Newly Diagnosed Ph+ ALL

July 5th 2023

Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.

Notable Advancements in Treatment for ALL

EP. 5: Notable Advancements in Treatment for ALL

July 12th 2023

Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.

Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALL

EP. 6: Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALL

July 12th 2023

With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.